Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine

Details

• Alternative Title:
  Pediatrics
• Personal Author:
  Chung, Jessie R. ; Flannery, Brendan ; Thompson, Mark G. ; Gaglani, Manjusha ; Jackson, Michael L. ; Monto, Arnold S. ; Nowalk, Mary Patricia ; Talbot, H. Keipp ; Treanor, John J. ; Belongia, Edward A. ; Murthy, Kempapura ; Jackson, Lisa A. ; Petrie, Joshua G. ; Zimmerman, Richard K. ; Griffin, Marie R. ; McLean, Huong Q. ; Fry, Alicia M.
• Description:
  BACKGROUND
  
  Few observational studies have evaluated the relative effectiveness of live attenuated (LAIV) and inactivated (IIV) influenza vaccines against medically attended laboratory-confirmed influenza.
  
  METHODS
  
  We analyzed US Influenza Vaccine Effectiveness Network data from participants aged 2 to 17 years during 4 seasons (2010–2011 through 2013–2014) to compare relative effectiveness of LAIV and IIV against influenza-associated illness. Vaccine receipt was confirmed via provider/electronic medical records or immunization registry. We calculated the ratio (odds) of influenza-positive to influenza-negative participants among those age-appropriately vaccinated with either LAIV or IIV for the corresponding season. We examined relative effectiveness of LAIV and IIV by using adjusted odds ratios (ORs) and 95% confidence intervals (CIs) from logistic regression.
  
  RESULTS
  
  Of 6819 participants aged 2 to 17 years, 2703 were age-appropriately vaccinated with LAIV (n = 637) or IIV (n = 2066). Odds of influenza were similar for LAIV and IIV recipients during 3 seasons (2010–2011 through 2012–2013). In 2013–2014, odds of influenza were significantly higher among LAIV recipients compared with IIV recipients 2 to 8 years old (OR 5.36; 95% CI, 2.37 to 12.13). Participants vaccinated with LAIV or IIV had similar odds of illness associated with influenza A/H3N2 or B. LAIV recipients had greater odds of illness due to influenza A/H1N1pdm09 in 2 seasons: 2010 to 2011 (OR 5.53; 95% CI, 1.35 to 22.76) and 2013–2014 (OR 2.65; 95% CI, 1.34 to 5.27).
  
  CONCLUSIONS
  
  We observed lower effectiveness of LAIV compared with IIV against influenza A/H1N1pdm09 but not A(H3N2) or B among children and adolescents, suggesting poor performance related to the LAIV A/H1N1pdm09 viral construct.
  
  
• Subjects:
  Adolescent Article Child Child, Preschool Female Humans Influenza, Human Influenza A Virus Influenza A Virus, H1N1 Subtype Influenza A Virus, H3N2 Subtype Influenza B Virus Influenza Vaccines Male Seasons United States Vaccines, Attenuated Vaccines, Inactivated

  More +
• Source:
  Pediatrics. 137(2):1-10
• Pubmed ID:
  26738884
• Pubmed Central ID:
  PMC4732363
• Document Type:
  Journal Article
• Funding:
  UL1 TR000005/TR/NCATS NIH HHS/United States ; U01IP000467/IP/NCIRD CDC HHS/United States ; UL1 RR024153/RR/NCRR NIH HHS/United States ; U01 IP000172/IP/NCIRD CDC HHS/United States ; U18 IP000172/IP/NCIRD CDC HHS/United States ; U01 IP000170/IP/NCIRD CDC HHS/United States ; UL1TR000005/TR/NCATS NIH HHS/United States ; U01 IP000183/IP/NCIRD CDC HHS/United States ; U18 IP000184/IP/NCIRD CDC HHS/United States ; U18 IP000183/IP/NCIRD CDC HHS/United States ; U01 IP000473/IP/NCIRD CDC HHS/United States ; CC999999/Intramural CDC HHS/United States ; U01 IP000466/IP/NCIRD CDC HHS/United States ; U01 IP000184/IP/NCIRD CDC HHS/United States ; U01IP000474/IP/NCIRD CDC HHS/United States ; U01 IP000471/IP/NCIRD CDC HHS/United States ; U01 IP000474/IP/NCIRD CDC HHS/United States ; U01 IP001037/IP/NCIRD CDC HHS/United States ; U01 IP000467/IP/NCIRD CDC HHS/United States ; U18 IP000170/IP/NCIRD CDC HHS/United States
• Volume:
  137
• Issue:
  2
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:88e9a006d3670fe26a1a38eb582dbaa84a95e9fa228d7a824793e2494ab1c9bd
• Download URL:
  https://stacks.cdc.gov/view/cdc/38155/cdc_38155_DS1.pdf
• File Type:
  [PDF - 340.98 KB ]